To our knowledge, only one prospective study has addressed this question in the post hoc analysis of a clinical trial on erythropoietin in patients with type 2 diabetes, anaemia and chronic kidney disease [15]. This evidence concerns the gene EPO and type 2 diabetes mellitus.